Concerns were raised following several publications that identified an increased risk for pancreatitis and pancreatic cancer in patients taking GLP-1 receptor agonists (GLP-1RA).1,2 A Food and Drug Administration (FDA) warning on pancreatic safety followed,3 urging both patients and health care professionals to report adverse events involving incretin mimetics to the FDA MedWatch program. This evidence concerns the gene GLP1R and pancreatic neoplasm.